COMP <GO>
IRMD vs LLY // GROSS PROFIT MARGIN
iRadimed Corporation (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: IRMD 3
— LLY 9
▲ GROSS PROFIT MARGIN LEADER: LLY
LAST: $85.74 (+2.16%) • MKT CAP: $1.10B
gross-margins
76.70%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
gross-margins
83.64%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRMD VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IRMD | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 76.70% | 83.64% | -6.94 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 37.70% | 32.36% | +5.34 | IRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.9x | 36.4x | -4.52 | IRMD | /valuation <GO> |
| Free Cash Flow Yield | 1.57% | 2.30% | -0.73 | LLY | /fcf-yield <GO> |
| Operating Margin | 31.20% | 40.21% | -9.01 | LLY | /operating-margins <GO> |
| Net Profit Margin | 26.80% | 31.90% | -5.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 14.40% | 45.51% | -31.11 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.37% | 0.49% | +0.88 | IRMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 9.29 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.6 | 66.6 | -40.96 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 41.0x | 26.3x | +14.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.10B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IRMD REV | LLY REV | IRMD GROSS % | LLY GROSS % | IRMD FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $83.8M | $65.18B | 76.7% | 83.0% | $17.2M | $16.81B |
| FY 2024 | $73.2M | $45.04B | 76.9% | 81.3% | $17.6M | $8.82B |
| FY 2023 | $65.6M | $34.12B | — | 79.3% | $13.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRMD // BETA —
LLY // BETA 0.51